June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study explores the potential of quercetin and kaempferol, two plant-derived flavonoids, as dual inhibitors of JAK3 kinase and 5-alpha reductase type 2 (5-AR2) for treating androgenetic alopecia (AGA). Using molecular docking simulations, quercetin showed the strongest binding affinity to JAK3 kinase, surpassing the reference drug tofacitinib, while both flavonoids demonstrated moderate binding to 5-AR2, within the inhibitory range for polyphenolic flavonoids. Quercetin's favorable ADMET profile, including suitable skin permeability and safety, highlights its promise for topical application. These findings support further research into these compounds as safer, natural alternatives for AGA management.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study explores the potential of quercetin and kaempferol, two plant-derived flavonoids, as dual inhibitors of JAK3 kinase and 5-alpha reductase type 2 (5-AR2) for treating androgenetic alopecia (AGA). Using molecular docking simulations, quercetin showed the strongest binding affinity to JAK3 kinase, surpassing the standard drug tofacitinib, while both flavonoids demonstrated moderate binding to 5-AR2, within the inhibitory range for polyphenolic flavonoids. Quercetin's favorable ADMET profile, including suitable skin permeability and safety, highlights its promise for topical application. These findings support further research into these compounds as safer, natural alternatives for AGA management.
June 2026 in “The Journal of Sexual Medicine” The study analyzed the FDA Adverse Event Reporting System (FAERS) database to investigate psychiatric adverse drug reactions (ADRs) associated with 5-alpha reductase inhibitors (5-ARIs), specifically finasteride and dutasteride. A total of 27,578 ADRs were reported for finasteride, with 29.3% being psychiatric, while dutasteride had 9,161 ADRs with 13.3% psychiatric. Finasteride showed a higher disproportional reporting of psychiatric ADRs compared to dutasteride, with common issues including depressive disorders, anxiety, suicidality, and libido disorders. Despite the findings, a causal relationship between these psychiatric issues and 5-ARIs cannot be conclusively determined, highlighting the need for ongoing surveillance and further studies to clarify their neuropsychiatric safety profile.
May 2026 in “International Journal of Dermatology” Higher levels of 3α-diol G are linked to more severe female pattern hair loss.
Finasteride and dutasteride can harm male reproductive health, affecting sperm and causing sexual dysfunction.
May 2026 in “Journal of the Egyptian Womenʼs Dermatologic Society” Intralesional methotrexate effectively treats patchy alopecia areata by reducing inflammation.
April 2026 in “Journal of the American Academy of Dermatology” Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.
February 2026 in “Case Reports in Dermatology” Finasteride can cause melasma, especially in people with darker skin.
Compounds in fluted pumpkin and African yam bean seed oils may help manage benign prostate hyperplasia.
February 2026 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
January 2026 in “Clinical Chemistry and Laboratory Medicine (CCLM)” The procedure accurately measures 5-alpha-dihydrotestosterone in blood, useful for standard tests.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
January 2026 in “Yonsei Medical Journal” Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
January 2026 in “Open Science Framework” Oral and topical 5-alpha reductase inhibitors affect DHT levels and hair density differently in treating hair loss.
November 2025 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
October 2025 in “International Journal of Cosmetic Science” USPlus® DERM may help hair growth and reduce hair loss.
October 2025 in “Journal of the Endocrine Society” Finasteride lowers cholesterol but doesn't reduce heart-related events.
July 2025 in “American Journal on Addictions” Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.
Teak leaf extract can help treat hair loss, and its effectiveness varies by geographic origin.
June 2025 in “Journal of Cosmetic Dermatology” Dutasteride 0.5 mg/day is the most effective treatment for male pattern hair loss.
June 2025 in “Pharmaceuticals” Finasteride use may increase suicidality risk, especially in young men.
February 2025 in “Iranian journal of pharmaceutical research” 
February 2025 in “Journal of Pre-Clinical and Clinical Research” The combination of finasteride, dutasteride, and minoxidil is generally safe for treating male hair loss with minimal side effects.
November 2024 in “Journal of Family Medicine and Primary Care” 5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
September 2024 in “Frontiers in Neuroendocrinology” 5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.
September 2024 in “Health of Man” Low-dose dutasteride effectively and safely promotes hair growth in men with androgenetic alopecia.
September 2024 in “Chemico-Biological Interactions” Finasteride improves heart function in obese and aging male rats by reducing oxidative stress and p53 protein levels.